Announcements Trials
Browse Landscape

Phase

Phase 2 40Phase 1 5Phase 1/2 4Phase 3 3Phase 4 2Phase EARLY_PHASE1 1

Status

Recruiting 2Not yet recruiting 2Active not recruiting 1

Sponsor Class

INDUSTRY 11NIH 6OTHER 5

Study Type

Interventional 5

Sponsor

Cancer Type

Breast 4Tumor-Agnostic 1CNS 1

Conditions

Breast Neoplasms 4Neoplasm Metastasis 2Neoplasms 1Brain Neoplasms 1

Interventions

Cyclophosphamide 416Radiotherapy 276fludarabine 238Gemcitabine 211Cisplatin 203Nivolumab 184pembrolizumab 183Paclitaxel 176Carboplatin 168Magnetic Resonance Spectroscopy 166fludarabine phosphate 156Irinotecan 135Bevacizumab 133Cytarabine 128Specimen Handling 124Capecitabine 124Temozolomide 123Radiosurgery 118Docetaxel 116Biopsy 116Ipilimumab 113Dexamethasone 113Radiation 111Oxaliplatin 110Fluorouracil 110Rituximab 108Etoposide 108Filgrastim 99Lenalidomide 98Everolimus 96

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1 × OTHER × trastuzumab deruxtecan × Clear all
NCT07086768 2026-06-03

Dose-Escalation and Dose-Expansion Study of BSI-082 Monotherapy and Combined Therapy in Patients With Advanced or Metastatic Solid Tumors

The University of Texas Health Science Center at San Antonio

Phase 1 Recruiting
57 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT07553390 2026-04-28

Phase 1b Study Of TRICK-NK In Combination With T-Dxd In Treatment-Refractory Breast Cancers

M.D. Anderson Cancer Center

Phase 1 Not yet recruiting
60 enrolled
Breast

Breast Neoplasms

NCT07454668 2026-03-06

Trastuzumab Deruxtecan + Stereotactic Radiosurgery (SRS) in HER2+ Breast Cancer Brain Metastases

Baptist Health South Florida

Phase 1 Not yet recruiting
20 enrolled
BreastCNS

Brain Neoplasms, Breast Neoplasms, Neoplasm Metastasis, Neoplasms

NCT05633979 2026-01-20

Phase 1b Study of EZH1/2 Inhibitor Valemetostat in Combination With Trastuzumab Deruxtecan in Subjects With HER2 Low/Ultra-low/Null Metastatic Breast Cancer

M.D. Anderson Cancer Center

Phase 1 Active not recruiting
17 enrolled
Breast

Breast Neoplasms

NCT06331169 2024-08-30

Anlotinib With Trastuzumab Deruxtecan for Previously Treated HER2-Low Advanced Breast Cancer

Fudan University

Phase 1 Recruiting
42 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡